Amicus Therapeutics Inc

NASDAQ:FOLD   12:40:06 AM EDT
11.68
-0.18 (-1.52%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)3.45B
Current PEN/A
Forward PE N/A
2yr Forward PE 29.2
See more stats
Estimates Current Quarter
Revenue$113.16 Million
Adjusted EPS-$0.06
See more estimates
10-Day MA$11.75
50-Day MA$12.64
200-Day MA$12.36
See more pivots

Amicus Therapeutics Inc Stock, NASDAQ:FOLD

47 Hulfish Street, Princeton, New Jersey 08542
United States of America
Phone: +1.609.662.2000
Number of Employees: 517

Description

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.